“The cost of HIV/AIDS medicine is expected to drop by 30 percent in Kenya, enabling more people to access life-prolonging drugs, after the World Health Organization (WHO) gave the green light to a local company manufacturing generics, The Star newspaper reported on Wednesday,” AlertNet reports. Universal Corporation received WHO prequalification status for its generic combination antiretroviral Lamozido, which “will enable the company to bid for international tenders to supply drugs to governments and non-governmental organizations, who in turn give them to people living with HIV/AIDS,” the news service writes (Migiro, 11/2).